Rachel N Grisham

20PUBLICATIONS
140CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer diagnosisCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Mar 25, 2026
A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Maria M Rubinstein, Jennifer Y Ge, Qin Zhou

|Aug 01, 2025
Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities.

Anne Knisely, Yibo Dai, Graham L Barlow

|May 06, 2025
Clinicopathologic Features, Molecular Landscape, and Prognostic Implications of Ovarian Low-grade Serous Tumors with Histologic Transformation.

M Herman Chui, Eun-Young Kang, Ryan M Kahn

|Nov 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.

Angela K Green, Qin Zhou, Alexia Iasonos

|Oct 07, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.

Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen

|Aug 16, 2024
Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer.

Mackenzie W Sullivan, Stephen Graves, Anusha Adkoli

Pageof 4

Frequent Collaborators

5 joint publications

Britta Weigelt

4 joint publications

Qin Zhou

3 joint publications

Ying L Liu

3 joint publications

Bradley J Monk